comparemela.com

Latest Breaking News On - Oxford astrazenaca - Page 2 : comparemela.com

Few health care workers turn up for second jab of Covid-19 vaccine Here s why

Few health care workers turn up for second jab of Covid-19 vaccine. Here’s why Few health care workers turn up for second jab of Covid-19 vaccine. Here’s why Most of the health care workers who have already received the first jab of Covid-19 did not turn up for the second shot. What could be the possible reason and is this a cause of concern. India Today TV’s Milan Sharma explains. advertisement UPDATED: February 15, 2021 16:49 IST India has started administering the second jab of Covid-19 vaccine but few health care workers are turning up for it | File photo from PTI

COVID-19 mutations perform a dazzling Darwinian dance

Advertisement We have not completed week six and already 2021 is turning out to be an interesting year. After much anticipation about the rollout of a vaccine, a major setback occurred on Sunday. The use of the Oxford-AstraZeneca vaccine in South Africa was stopped because of lower effectiveness against the so-called South Africa variant – more formally known as B.1.351. Prime Minister Scott Morrison tours the AstraZeneca laboratories in NSW last year after the government signed an agreement with the company to produce the vaccine. Credit:Nick Moir It has been found that the Oxford-AstraZeneca vaccine has poor protection against mild and moderate illness from B.1.351 among young adults. The vaccine may, hopefully, still be effective against serious illness, but definitive evidence on this is not in.

Covid: Johnson & Johnson single shot Janssen vaccine shown to work, but not as well as some two-shot rivals

play-icon Video report by ITV News Science Editor Tom Clarke Johnson & Johnson s one-dose coronavirusvaccine - which the UK has ordered 30 million doses of - has been shown to protect against Covid-19, but not as well as some two-shot rivals, trials have shown. The single-shot Janssen vaccine was found to be 66% effective overall at preventing moderate to severe illness, and much more protective 85% against the most serious symptoms. play-icon Professor Peter Openshaw from Imperial College London: It s extraordinary news isn t it? It s such a success for the vaccine development field as a whole and to see this announcement that the Johnson & Johnson vaccine - which is on the list of those that have been procured by the UK vaccine taskforce - also looks so effective is wonderful.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.